Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.4% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price rose 8.4% during trading on Thursday. The stock traded as high as $4.02 and last traded at $4.0550. Approximately 19,711,231 shares traded hands during trading, an increase of 3% from the average daily volume of 19,182,031 shares. The stock had previously closed at $3.74.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of research reports. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Trading Up 13.0%

The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $3.61 and its 200-day simple moving average is $3.41. The company has a market capitalization of $2.26 billion, a PE ratio of -4.05 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same period in the previous year, the company earned ($0.41) EPS. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director owned 162,156 shares in the company, valued at approximately $810,780. The trade was a 13.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 157,408 shares of company stock worth $643,576. 6.65% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. MCF Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the second quarter worth about $27,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at about $39,000. MQS Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $41,000. Fund Advisors of America Inc FL purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at about $45,000. Finally, QRG Capital Management Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $47,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.